# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Muhammad Ali (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX001-SYN
- Date: 2026-02-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Celeste Moreau, MD
- Calendar frame: modern shifted

## Subjective

The patient participates in this fictional visit for establishing primary care for Parkinson's disease: motor, non-motor, fall-risk, and orthostatic assessment. **S**

## Objective

Hemoglobin: 14.6 g/dL; Sodium: 140 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 1.02 mg/dL; eGFR: 87 mL/min/1.73 m²; Glucose: 92 mg/dL; Calcium: 9.5 mg/dL; Vitamin B12: 512 pg/mL; TSH: 1.8 mIU/L; MoCA: 27; PHQ-9: 3. All results are synthetic.

BP 128/78 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 102 kg; BMI 28 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Parkinson's disease, young onset (diagnosed at 42), Hoehn and Yahr stage 2.5, without dyskinesia or motor fluctuations; Hypokinetic dysarthria with soft speech due to Parkinson's disease. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Continued without change: Carbidopa-levodopa 25/100 mg oral tablet, one tablet by mouth three times daily **S**

## Plan

- Review the levodopa dose and timing at every visit for slowness, wearing-off, and dyskinesia; take doses 30 minutes before meals; check supine and three-minute standing blood pressure after any change; avoid dopamine-blocking drugs such as metoclopramide, prochlorperazine, and most antipsychotics. Guideline: Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee (2021); The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension (2017); CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026) **S**
- Movement disorders neurology consultation to confirm the diagnosis against the MDS criteria, adjust levodopa, plan rehabilitation, and advise on genetic testing. Guideline: Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee (2021); MDS clinical diagnostic criteria for Parkinson's disease (2015); CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026) **S**
- Monitor on the CMID schedule: motor examination, Hoehn and Yahr stage, fall check, psychosis and impulse-control questions, and medication review every visit; cognition, mood, sleep, autonomic symptoms, swallowing, speech, and driving yearly; dental examination every six months. Guideline: MDS clinical diagnostic criteria for Parkinson's disease (2015); CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026) **S**
- Advance care planning: name a health care agent and record goals of care, and revisit with any change in stage. Guideline: CMID: Clinical Monitoring Intelligence Database, Parkinson's disease monograph (2026) **S**
